Eli Lilly and Company (LLY) Presents at UBS Biopharma 2023 Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) UBS Biopharma 2023 Conference November 8, 2023 3:00 PM ET Company Participants Patrik Jonsson - President, Lilly Immunology Conference Call Participants Trung Huyn...
Eli Lilly's Tirzepatide approved in the EU days after US and UK approval
Eli Lilly (LLY) stock price movement has experienced a whirlwind since Wednesday's approval of its diabetes medication, Tirzepatide, for chronic weight management in the United States and the Unite...
Where Will Eli Lilly Be in 5 Years?
Eli Lilly is pulling out all the stops to gain market share in a pair of key markets. It'll face stiff opposition from Novo Nordisk, among other contenders.
EU regulator backs Eli Lilly's Mounjaro for weight management
Europe's medicines regulator said on Friday its committee had recommended changing authorization terms for Eli Lilly's drug Mounjaro to include weight-management.
Will Eli Lilly's Zepbound be the next big weight-loss drug?
Eli Lilly & Co. NYSE: LLY reversed lower on November 9. This came after LLY stock advanced 3.20% after the company got regulators' OK for its weight-loss drug Zepbound.
British regulator confirms review of new pen for Lilly's Mounjaro drug
Britain's drug regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), on Friday confirmed that it is reviewing a new injection pen that Eli Lilly plans to use for the U.S. drugm...
Eli Lilly CEO: We know there's high demand for weight-loss drugs and we're ready to meet it
David Ricks, Eli Lilly CEO, joins 'Closing Bell Overtime' to talk the FDA's approval of its new weight-loss drug, keeping up with demand for the drug, competition in the space and more.
Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugs
Former FDA commissioner Dr. Scott Gottlieb joins 'Power Lunch' to discuss Eli Lilly's highly anticipated weight-loss drug Zepbound, the demand and supply equation in the weight-loss drug space, and...
Lilly Takes First Jab in Obesity Drug Showdown
Eli Lilly says its obesity drug's list price is about 20% lower than Novo's Wegovy.
Eli Lilly's Big Win In The Obesity Space Just Got Bigger
Eli Lilly received FDA approval to sell tirzepatide for obesity treatment, expanding its market beyond diabetes. Shares of Eli Lilly jumped 3.2% on the news, resulting in a $17.3 billion increase i...
Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?
Eli Lilly is eager to steal market share from Novo Nordisk's drug Ozempic. Creating medicines that don't have certain side effects is one strategy.
Eli Lilly: still seeking UK approval on pen for weight-loss drug
Eli Lilly on Thursday said it has not yet gained approval in Britain for the injection pen it plans to use for its Mounjaro drug against obesity and diabetes, adding to uncertainty over timing of t...
'Wonder' diabetes drug Mounjaro approved in the UK
Diabetes blockbuster Mounjaro has been approved for use by the UK drugs agency MHRA after two clinical trials showed patients taking shed between 16%-22% of their weight in little more than a year....
BofA'S Meacham on what's next for Eli Lilly after FDA approves obesity drug
Geoff Meacham, Bank of America, joins 'Fast Money' to talk the FDA's approval of Eli Lilly's obesity drug.
FDA approves Eli Lilly's Mounjaro for weight loss
The Food and Drug Administration has approved Eli Lilly and Company's (LLY) Mounjaro, under the name Zepbound, for the treatment of obesity. Previously, Novo Nordisk's (NVO) Wegovy and Ozempic were...
Related Companies